– USA, NY – Tyme, Inc. (OTC QB: TYMI), a research and development company focused on developing drug candidates for the treatment of cancer, today announced the appointment of its Board of Directors. In addition to Chief Executive Officer, Steve Hoffman, and Chief Operating Officer, Michael Demurjian, Tyme’s Board of Directors includes Patrick G. LePore, Gerald Sokol and Tim Tyson. Former HHS Secretary, Tommy Thompson, currently an Advisor to the Board, will become a Director in the third quarter of 2015.
“We are extremely proud to have gathered such a notable Board of Directors to help lead Tyme,” said CEO Steve Hoffman. “We believe we have the potential to become a major player in the oncology space and feel confident that the collective – and highly impressive – experience of our Board will provide the strategic guidance necessary to advance the development of our novel, proprietary treatment regimen, which we believe to be a first-in-class drug that harnesses the body’s own immune defenses to fight tumor cells.”
About Patrick G. LePore, Director
Mr. LePore has extensive operational and board experience in the private and public sectors of the pharmaceutical industry, which includes building and running a large pharmaceutical service business. He was formerly Chairman, CEO and President of Par Pharmaceuticals, Inc. Under his leadership, Par increased its value and was sold in a private transaction to TPG, a leading global private investment firm, for approximately $2 billion. He currently serves Par as its executive chairman.
He began his career with Hoffmann La Roche before founding Boron LePore and Associates, a medical communications company, which he took public in 1997. His expertise spans virtually all areas of executive management, including human resources, executive development, strategic planning, mergers and acquisition, business development, investor relations and corporate governance. Throughout his career, Mr. LePore has served on nonprofit and corporate boards. He is currently the Chairman of Agene Bio and serves on the boards of PharMerica (NYSE:PMC) and Villanova University, his alma mater. Mr. LePore also holds an MBA from Farleigh Dickinson University.
About Gerald Sokol MD, MSc, FCP, Director
Dr. Sokol is a board member and partner of Florida Cancer Specialists and Research Institute, the largest independent medical oncology/hematology practice in the United States with more than 170 physicians and 110 nurse practitioners. He also has been the Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital and has had leadership roles in building more than 10 successful cancer centers. In addition to his medical practice, Dr. Sokol was a senior regulatory scientist and officer for 27 years on the review staff of the FDA, where he composed more than 300 white papers, IND and NDA reviews, and opinion papers. He is a decorated retired Captain in the US Navy and served as Commanding Officer of the unit at the Uniformed Services University, where he currently is a professor in Medicine and Pharmacology.
Dr. Sokol graduated from Indiana University’s Combined Degree Program in Experimental Medicine with a master’s degree in Pharmacology and an MD. He completed his training at the Massachusetts General Hospital, Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology. He is board certified in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and Quality Assurance and Utilization Review. He is also certified in Skin Cancer Medicine from the University of Queensland.
About Tim Tyson, Director
Mr. Tyson is currently President of Alkaloida Chemical Company Zrt, which manufactures and distributes pharmaceutical ingredients, pharmaceutical finished products, and synthetic intermediates. He brings more than 30-years of pharmaceutical industry experience to Tyme. Mr. Tyson previously served as CEO for companies including Caldera Pharmaceuticals Inc. and Aptuit. He also served as President of Valeant Pharmaceuticals International and President of Global Manufacturing and Supply for GlaxoSmithKline plc. Mr. Tyson serves as a Director on the Boards of numerous pharmaceutical, industry, academic and not-for-profit organizations.
Mr. Tyson is a 1974 graduate of the United States Military Academy at West Point. He served as an Officer in the United States Army from 1974 to 1979 and spent 14 years in the United States Army Reserves. In 2002, he received a Bicentennial Leadership Award from the United States Military Academy at West Point. Mr. Tyson received a Master in Business Administration and Master in Public Administration from Jacksonville State University in 1979 and 1976 respectively and, in 2007, was the university named him its Alumnus of the Year.
About Tommy G. Thompson, Advisor
Governor Thompson is the Chairman and Chief Executive Officer of Thompson Holdings, the former United States Health and Human Services (HHS) Secretary and the four-term Governor of Wisconsin. Growing from his work in public office, Governor Thompson formed Thompson Holdings to develop innovative solutions to the health care challenges facing American families, businesses, communities, states and the entire nation. These efforts focus on improving the use of information technology in hospitals, clinics and doctors’ offices; promoting healthier lifestyles; strengthening and modernizing Medicare and Medicaid; and expanding the use of medical diplomacy around the world.
From 2005 until 2009, Governor Thompson served as a senior advisor at the consulting firm Deloitte LLP. He was the founding independent chairman of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation’s most pressing health care and public health challenges. Governor Thompson also has served as a senior partner at the law firm of Akin, Gump, Strauss, Hauer, & Feld LLP and is a former president and chairman of Logistics Health, Inc. He currently is the chairman of Physicians Realty Trust and TherapeuticsMD, Inc. and is a board director for, Centene Corporation, C.R. Bard, Inc., Cytori Therapeutics, Inc. and United Therapeutics Corporation.
Tyme is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic characteristics of cancer cells as well as activating the endogenous immune response against tumors. Tyme’s approach is hypothesized to permit selective elimination of cancer cells, while simultaneously improving patients’ well-being, particularly with respect to pain severity and functional independence.
Tyme is currently developing for use in humans SM-88, our proprietary compound, which we believe to be a first-in-class drug that harnesses the body’s own immune defenses to fight tumor cells. SM-88 is a novel combination drug that synergistically target the unique metabolic features of cancer cells, thus providing a selective method of altering the susceptibility of cancer cells to oxidative stress. Tyme has completed a proof-of-concept clinical study for SM-88 in late-stage cancer patients with relapsed or highly refractory disease and is working towards submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration, with the goal of beginning a randomized clinical trial in multiple U.S. centers in the near future. We anticipate an IND submission to the FDA by the second quarter with trials commencing in third quarter.
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.